Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)

Giuseppina Oderda, Peter Shcherbakov, Patrick Bontems, Pedro Urruzuno, Claudio Romano, Frederic Gottrand, M. Jose Martinez Gómez, Alberto Ravelli, Paolo Gandullia, Elefteria Roma, Sami Cadranel, Costantino De Giacomo, Roberto Berni Canani, Vincenzo Rutigliano, Ender Pehlivanoglu, Nicolas Kalach, Paola Roggero, Danuta Celinska-Cedro, Brendan Drumm, Thomas CasswallMarja Ashorn, Sanda Nousia Arvanitakis

Research output: Contribution to journalArticle

Abstract

Background and Aim: Data on the eradication treatment for childhood Helicobacter pylori are scanty. A register was established on the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) website to collect data on treatment performed by European pediatricians to ascertain what is practiced in the field. Subjects: From January 2001 to December 2002, information on 597 children were entered by 23 European Centers, but only data of 518 treated children were completed and analyzed (86.7%, 262 male subjects, median age 9 years, range 1-14). According to their nationality, 226 children were from Southern Europe, 132 from Eastern Europe, 68 from Western Europe, and 4 from northern Europe, 68 from North Africa, and 20 from Asia. At endoscopy, 454 children had gastritis and 64 had ulcer (12.3%). Antibiotic sensitivity, tested in 361 cases, revealed 18% clarithromycin-resistant and 19% metronidazole-resistant H. pylori strains. Results: Treatment was performed for 1 week in 388 and for 2 weeks in 130 children. Antibiotics were associated with proton pump inhibitors (PPI) in 345 and with bismuth in 121 children. Triple therapy was given to 485 children, dual therapy to 26, quadruple to 7. Follow-up data, by 13C-Urea-Breath Test or histology or both, were available for 480 children. Overall eradication rate was 65.6%, significantly higher in children with ulcer (79.7%) than without (63.9%, p =.001). When given as first treatment, bismuth-containing triple therapies were more efficacious than PPI-containing ones (77% versus 64%, p =.02, OR 1.88, 95% CI 1.1-3.3). Twenty-seven different treatment regimens were used, but only six were administered to at least 18 children (range 18-157). There was no difference between treatments given for 1 or 2 weeks, or given as first or second therapies. Conclusion: European pediatricians entering data in the register used 27 different regimens. Bismuth-containing therapies resulted in higher eradication rate. Omeprazole-containing triple therapies were the most used although their efficacy was low. Therapies recommended for adults do not appear to be suitable for children.

Original languageEnglish
Pages (from-to)150-156
Number of pages7
JournalHelicobacter
Volume12
Issue number2
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Helicobacter pylori
Pediatrics
Bismuth
Therapeutics
Proton Pump Inhibitors
Gastroenterology
Ulcer
Anti-Bacterial Agents
Northern Africa
Eastern Europe
Breath Tests
Clarithromycin
Omeprazole
Metronidazole
Gastritis
Ethnic Groups
Endoscopy
Urea
Histology

Keywords

  • Antibiotic susceptibility
  • Bismuth salts
  • Childhood gastritis
  • Childhood ulcer
  • Eradication treatment
  • Helicobacter pylori
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Gastroenterology
  • Microbiology

Cite this

Oderda, G., Shcherbakov, P., Bontems, P., Urruzuno, P., Romano, C., Gottrand, F., ... Arvanitakis, S. N. (2007). Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH). Helicobacter, 12(2), 150-156. https://doi.org/10.1111/j.1523-5378.2007.00485.x

Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH). / Oderda, Giuseppina; Shcherbakov, Peter; Bontems, Patrick; Urruzuno, Pedro; Romano, Claudio; Gottrand, Frederic; Gómez, M. Jose Martinez; Ravelli, Alberto; Gandullia, Paolo; Roma, Elefteria; Cadranel, Sami; Giacomo, Costantino De; Canani, Roberto Berni; Rutigliano, Vincenzo; Pehlivanoglu, Ender; Kalach, Nicolas; Roggero, Paola; Celinska-Cedro, Danuta; Drumm, Brendan; Casswall, Thomas; Ashorn, Marja; Arvanitakis, Sanda Nousia.

In: Helicobacter, Vol. 12, No. 2, 04.2007, p. 150-156.

Research output: Contribution to journalArticle

Oderda, G, Shcherbakov, P, Bontems, P, Urruzuno, P, Romano, C, Gottrand, F, Gómez, MJM, Ravelli, A, Gandullia, P, Roma, E, Cadranel, S, Giacomo, CD, Canani, RB, Rutigliano, V, Pehlivanoglu, E, Kalach, N, Roggero, P, Celinska-Cedro, D, Drumm, B, Casswall, T, Ashorn, M & Arvanitakis, SN 2007, 'Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)', Helicobacter, vol. 12, no. 2, pp. 150-156. https://doi.org/10.1111/j.1523-5378.2007.00485.x
Oderda G, Shcherbakov P, Bontems P, Urruzuno P, Romano C, Gottrand F et al. Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH). Helicobacter. 2007 Apr;12(2):150-156. https://doi.org/10.1111/j.1523-5378.2007.00485.x
Oderda, Giuseppina ; Shcherbakov, Peter ; Bontems, Patrick ; Urruzuno, Pedro ; Romano, Claudio ; Gottrand, Frederic ; Gómez, M. Jose Martinez ; Ravelli, Alberto ; Gandullia, Paolo ; Roma, Elefteria ; Cadranel, Sami ; Giacomo, Costantino De ; Canani, Roberto Berni ; Rutigliano, Vincenzo ; Pehlivanoglu, Ender ; Kalach, Nicolas ; Roggero, Paola ; Celinska-Cedro, Danuta ; Drumm, Brendan ; Casswall, Thomas ; Ashorn, Marja ; Arvanitakis, Sanda Nousia. / Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH). In: Helicobacter. 2007 ; Vol. 12, No. 2. pp. 150-156.
@article{46d21a06a5bb4caebcb0e16fee00a69f,
title = "Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)",
abstract = "Background and Aim: Data on the eradication treatment for childhood Helicobacter pylori are scanty. A register was established on the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) website to collect data on treatment performed by European pediatricians to ascertain what is practiced in the field. Subjects: From January 2001 to December 2002, information on 597 children were entered by 23 European Centers, but only data of 518 treated children were completed and analyzed (86.7{\%}, 262 male subjects, median age 9 years, range 1-14). According to their nationality, 226 children were from Southern Europe, 132 from Eastern Europe, 68 from Western Europe, and 4 from northern Europe, 68 from North Africa, and 20 from Asia. At endoscopy, 454 children had gastritis and 64 had ulcer (12.3{\%}). Antibiotic sensitivity, tested in 361 cases, revealed 18{\%} clarithromycin-resistant and 19{\%} metronidazole-resistant H. pylori strains. Results: Treatment was performed for 1 week in 388 and for 2 weeks in 130 children. Antibiotics were associated with proton pump inhibitors (PPI) in 345 and with bismuth in 121 children. Triple therapy was given to 485 children, dual therapy to 26, quadruple to 7. Follow-up data, by 13C-Urea-Breath Test or histology or both, were available for 480 children. Overall eradication rate was 65.6{\%}, significantly higher in children with ulcer (79.7{\%}) than without (63.9{\%}, p =.001). When given as first treatment, bismuth-containing triple therapies were more efficacious than PPI-containing ones (77{\%} versus 64{\%}, p =.02, OR 1.88, 95{\%} CI 1.1-3.3). Twenty-seven different treatment regimens were used, but only six were administered to at least 18 children (range 18-157). There was no difference between treatments given for 1 or 2 weeks, or given as first or second therapies. Conclusion: European pediatricians entering data in the register used 27 different regimens. Bismuth-containing therapies resulted in higher eradication rate. Omeprazole-containing triple therapies were the most used although their efficacy was low. Therapies recommended for adults do not appear to be suitable for children.",
keywords = "Antibiotic susceptibility, Bismuth salts, Childhood gastritis, Childhood ulcer, Eradication treatment, Helicobacter pylori, Proton pump inhibitor",
author = "Giuseppina Oderda and Peter Shcherbakov and Patrick Bontems and Pedro Urruzuno and Claudio Romano and Frederic Gottrand and G{\'o}mez, {M. Jose Martinez} and Alberto Ravelli and Paolo Gandullia and Elefteria Roma and Sami Cadranel and Giacomo, {Costantino De} and Canani, {Roberto Berni} and Vincenzo Rutigliano and Ender Pehlivanoglu and Nicolas Kalach and Paola Roggero and Danuta Celinska-Cedro and Brendan Drumm and Thomas Casswall and Marja Ashorn and Arvanitakis, {Sanda Nousia}",
year = "2007",
month = "4",
doi = "10.1111/j.1523-5378.2007.00485.x",
language = "English",
volume = "12",
pages = "150--156",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)

AU - Oderda, Giuseppina

AU - Shcherbakov, Peter

AU - Bontems, Patrick

AU - Urruzuno, Pedro

AU - Romano, Claudio

AU - Gottrand, Frederic

AU - Gómez, M. Jose Martinez

AU - Ravelli, Alberto

AU - Gandullia, Paolo

AU - Roma, Elefteria

AU - Cadranel, Sami

AU - Giacomo, Costantino De

AU - Canani, Roberto Berni

AU - Rutigliano, Vincenzo

AU - Pehlivanoglu, Ender

AU - Kalach, Nicolas

AU - Roggero, Paola

AU - Celinska-Cedro, Danuta

AU - Drumm, Brendan

AU - Casswall, Thomas

AU - Ashorn, Marja

AU - Arvanitakis, Sanda Nousia

PY - 2007/4

Y1 - 2007/4

N2 - Background and Aim: Data on the eradication treatment for childhood Helicobacter pylori are scanty. A register was established on the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) website to collect data on treatment performed by European pediatricians to ascertain what is practiced in the field. Subjects: From January 2001 to December 2002, information on 597 children were entered by 23 European Centers, but only data of 518 treated children were completed and analyzed (86.7%, 262 male subjects, median age 9 years, range 1-14). According to their nationality, 226 children were from Southern Europe, 132 from Eastern Europe, 68 from Western Europe, and 4 from northern Europe, 68 from North Africa, and 20 from Asia. At endoscopy, 454 children had gastritis and 64 had ulcer (12.3%). Antibiotic sensitivity, tested in 361 cases, revealed 18% clarithromycin-resistant and 19% metronidazole-resistant H. pylori strains. Results: Treatment was performed for 1 week in 388 and for 2 weeks in 130 children. Antibiotics were associated with proton pump inhibitors (PPI) in 345 and with bismuth in 121 children. Triple therapy was given to 485 children, dual therapy to 26, quadruple to 7. Follow-up data, by 13C-Urea-Breath Test or histology or both, were available for 480 children. Overall eradication rate was 65.6%, significantly higher in children with ulcer (79.7%) than without (63.9%, p =.001). When given as first treatment, bismuth-containing triple therapies were more efficacious than PPI-containing ones (77% versus 64%, p =.02, OR 1.88, 95% CI 1.1-3.3). Twenty-seven different treatment regimens were used, but only six were administered to at least 18 children (range 18-157). There was no difference between treatments given for 1 or 2 weeks, or given as first or second therapies. Conclusion: European pediatricians entering data in the register used 27 different regimens. Bismuth-containing therapies resulted in higher eradication rate. Omeprazole-containing triple therapies were the most used although their efficacy was low. Therapies recommended for adults do not appear to be suitable for children.

AB - Background and Aim: Data on the eradication treatment for childhood Helicobacter pylori are scanty. A register was established on the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) website to collect data on treatment performed by European pediatricians to ascertain what is practiced in the field. Subjects: From January 2001 to December 2002, information on 597 children were entered by 23 European Centers, but only data of 518 treated children were completed and analyzed (86.7%, 262 male subjects, median age 9 years, range 1-14). According to their nationality, 226 children were from Southern Europe, 132 from Eastern Europe, 68 from Western Europe, and 4 from northern Europe, 68 from North Africa, and 20 from Asia. At endoscopy, 454 children had gastritis and 64 had ulcer (12.3%). Antibiotic sensitivity, tested in 361 cases, revealed 18% clarithromycin-resistant and 19% metronidazole-resistant H. pylori strains. Results: Treatment was performed for 1 week in 388 and for 2 weeks in 130 children. Antibiotics were associated with proton pump inhibitors (PPI) in 345 and with bismuth in 121 children. Triple therapy was given to 485 children, dual therapy to 26, quadruple to 7. Follow-up data, by 13C-Urea-Breath Test or histology or both, were available for 480 children. Overall eradication rate was 65.6%, significantly higher in children with ulcer (79.7%) than without (63.9%, p =.001). When given as first treatment, bismuth-containing triple therapies were more efficacious than PPI-containing ones (77% versus 64%, p =.02, OR 1.88, 95% CI 1.1-3.3). Twenty-seven different treatment regimens were used, but only six were administered to at least 18 children (range 18-157). There was no difference between treatments given for 1 or 2 weeks, or given as first or second therapies. Conclusion: European pediatricians entering data in the register used 27 different regimens. Bismuth-containing therapies resulted in higher eradication rate. Omeprazole-containing triple therapies were the most used although their efficacy was low. Therapies recommended for adults do not appear to be suitable for children.

KW - Antibiotic susceptibility

KW - Bismuth salts

KW - Childhood gastritis

KW - Childhood ulcer

KW - Eradication treatment

KW - Helicobacter pylori

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33847010115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847010115&partnerID=8YFLogxK

U2 - 10.1111/j.1523-5378.2007.00485.x

DO - 10.1111/j.1523-5378.2007.00485.x

M3 - Article

C2 - 17309752

AN - SCOPUS:33847010115

VL - 12

SP - 150

EP - 156

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 2

ER -